MONTGOMERY L ROBERTS D.O.
Prescription History 1124089321
Internal Medicine - Pulmonary Disease in Shawnee Mission, KS

NPI Status: Active since March 29, 2006

Contact Information

7450 KESSLER ST STE 204
SHAWNEE MISSION, KS
ZIP 66204
Phone: (913) 632-9770
Fax: (913) 632-9799

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MONTGOMERY L ROBERTS D.O., an active Pulmonary Disease specialist practicing in Shawnee Mission, KS. Our medical registry currently tracks 28 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 1,217 documented patient claims. Among these therapy options, the most frequently utilized medication is Albuterol Sulfate Hfa, which accounts for 244 claims alone.


Advair Diskus

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 21
30-Day Fills 32.0
Days Supply 960
KS State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills26.0
Peer Average Days Supply775
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $14,348.88 across this reporting matrix range.

Provider Avg Cost Per Claim

$683.28

State Avg Cost Per Claim

$524.25

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Albuterol Sulfate

Generic Formulation: Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 316
KS State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills22.1
Peer Average Days Supply304
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $478.09 across this reporting matrix range.

Provider Avg Cost Per Claim

$29.88

State Avg Cost Per Claim

$36.75

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Albuterol Sulfate Hfa

Generic Formulation: Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 244
30-Day Fills 318.5
Days Supply 8,043
KS State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills55.3
Peer Average Days Supply1,349
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 442.2% higher than the standard regional baseline profile for KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,782.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$31.90

State Avg Cost Per Claim

$49.71

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Alprazolam

Generic Formulation: AlprazolamSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 19
30-Day Fills 23.0
Days Supply 546
KS State Average Benchmarks
Peer Average Claims61.0
Peer Average 30-Day Fills66.0
Peer Average Days Supply1,745
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 68.9% less volume than the regional standard for practitioners inside KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $134.70 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.09

State Avg Cost Per Claim

$10.41

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238)

Therapeutic Applications

Alprazolam is used to treat anxiety and panic disorders. It belongs to a class of medications called benzodiazepines which act on the brain and nerves (central nervous system) to produce a calming effect. It works by enhancing the effects of a certain natural chemical in the body (GABA).

Amoxicillin-Clavulanate Potass

Generic Formulation: Amoxicillin/Potassium ClavSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 93
KS State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills22.1
Peer Average Days Supply207
Conservative Utilization

This provider writes prescriptions for this formulation 45.5% less frequently than the standard regional baseline metric for practitioners inside KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $99.33 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.28

State Avg Cost Per Claim

$12.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fixed-ratio combination of amoxicillin trihydrate and potassium clavulanate.

Therapeutic Applications

Amoxicillin/clavulanic acid is a combination penicillin-type antibiotic used to treat a wide variety of bacterial infections. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Anoro Ellipta

Generic Formulation: Umeclidinium Brm/Vilanterol TrSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 57
30-Day Fills 68.0
Days Supply 2,040
KS State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills36.1
Peer Average Days Supply1,072
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 96.6% higher than the standard regional baseline profile for KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $33,378.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$585.59

State Avg Cost Per Claim

$582.45

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: umeclidinium and vilanterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Vilanterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Umeclidinium/vilanterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as vilanterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Arnuity Ellipta

Generic Formulation: Fluticasone FuroateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
KS State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills20.4
Peer Average Days Supply610
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,985.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$306.60

State Avg Cost Per Claim

$282.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Azithromycin

Generic Formulation: AzithromycinSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 51
30-Day Fills 63.0
Days Supply 1,562
KS State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills33.4
Peer Average Days Supply314
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 64.5% higher than the standard regional baseline profile for KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $956.44 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.75

State Avg Cost Per Claim

$10.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Bevespi Aerosphere

Generic Formulation: Glycopyrrolate/Formoterol FumSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 16
30-Day Fills 24.0
Days Supply 720
KS State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills20.2
Peer Average Days Supply606
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $11,011.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$688.19

State Avg Cost Per Claim

$485.71

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you maintain your normal activities and decreases time lost from work or school. This inhaler contains 2 medications: glycopyrrolate and formoterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Glycopyrrolate belongs to a class of drugs known as anticholinergics. Formoterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. Glycopyrrolate/formoterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as formoterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Breo Ellipta

Generic Formulation: Fluticasone/VilanterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 60
30-Day Fills 85.0
Days Supply 2,550
KS State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills36.2
Peer Average Days Supply1,076
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 106.9% higher than the standard regional baseline profile for KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $36,146.60 across this reporting matrix range.

Provider Avg Cost Per Claim

$602.44

State Avg Cost Per Claim

$502.63

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to prevent and decrease symptoms (wheezing and trouble breathing) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, including chronic bronchitis and emphysema). This inhaler contains 2 medications: fluticasone and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the swelling of the airways in the lungs to make breathing easier. Vilanterol belongs to a class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. When used alone, long-acting beta agonists (like vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Breztri Aerosphere

Generic Formulation: Budesonide/Glycopyr/FormoterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 39
30-Day Fills 54.0
Days Supply 1,620
KS State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills34.7
Peer Average Days Supply1,035
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 30.0% more claims than the standard regional baseline profile for KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $36,183.50 across this reporting matrix range.

Provider Avg Cost Per Claim

$927.78

State Avg Cost Per Claim

$743.09

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you maintain your normal activities and decreases time lost from work or school. This inhaler contains 3 medications: budesonide, glycopyrrolate, and formoterol. Budesonide works by reducing the irritation and swelling of the airways. Budesonide belongs to a class of drugs known as corticosteroids. Glycopyrrolate and formoterol work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Glycopyrrolate belongs to a class of drugs known as anticholinergics. Formoterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This medication is not approved to treat asthma.

Cefuroxime

Generic Formulation: Cefuroxime AxetilSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 27
30-Day Fills 27.0
Days Supply 225
KS State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills24.2
Peer Average Days Supply223
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $432.24 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.01

State Avg Cost Per Claim

$27.59

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cephalosporin antibiotic.

Therapeutic Applications

Cefuroxime is used to treat a wide variety of bacterial infections. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Combivent Respimat

Generic Formulation: Ipratropium/Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 27.0
Days Supply 810
KS State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills22.2
Peer Average Days Supply629
Conservative Utilization

This provider writes prescriptions for this formulation 31.6% less frequently than the standard regional baseline metric for practitioners inside KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $13,119.51 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,009.19

State Avg Cost Per Claim

$580.47

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to treat and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). This product contains 2 medications: ipratropium and albuterol (also known as salbutamol). Both drugs work by relaxing the muscles around the airways so that the airways open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Dupixent Pen

Generic Formulation: DupilumabSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 364
KS State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills22.3
Peer Average Days Supply611
Conservative Utilization

This provider writes prescriptions for this formulation 38.1% less frequently than the standard regional baseline metric for practitioners inside KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $50,374.35 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,874.95

State Avg Cost Per Claim

$3,783.97

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain skin conditions (eczema, prurigo nodularis) and a certain esophagus problem (eosinophilic esophagitis). It is also used along with other medications to help control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. In addition, dupilumab may be used to reduce symptoms caused by nasal polyps and the long-term swelling of the sinuses and nasal passage (chronic rhinosinusitis with nasal polyposis). Dupilumab belongs to a class of drugs known as monoclonal antibodies. It works by blocking certain natural proteins in your body (interleukin-4 and interleukin-13) that may cause inflammation and swelling. This medication should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Fluticasone Propionate

Generic Formulation: Fluticasone PropionateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 15
30-Day Fills 42.0
Days Supply 1,260
KS State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills72.5
Peer Average Days Supply2,162
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 66.7% less volume than the regional standard for practitioners inside KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $204.58 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.64

State Avg Cost Per Claim

$17.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Fluticasone-Salmeterol

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 33
30-Day Fills 67.0
Days Supply 2,010
KS State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills25.7
Peer Average Days Supply769
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 65.0% higher than the standard regional baseline profile for KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $12,400.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$375.78

State Avg Cost Per Claim

$218.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Incruse Ellipta

Generic Formulation: Umeclidinium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 19.0
Days Supply 570
KS State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills29.0
Peer Average Days Supply859
Conservative Utilization

This provider writes prescriptions for this formulation 43.5% less frequently than the standard regional baseline metric for practitioners inside KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,349.99 across this reporting matrix range.

Provider Avg Cost Per Claim

$565.38

State Avg Cost Per Claim

$471.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Umeclidinium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Montelukast Sodium

Generic Formulation: Montelukast SodiumSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 29
30-Day Fills 85.0
Days Supply 2,550
KS State Average Benchmarks
Peer Average Claims56.0
Peer Average 30-Day Fills114.1
Peer Average Days Supply3,381
Conservative Utilization

This provider writes prescriptions for this formulation 48.2% less frequently than the standard regional baseline metric for practitioners inside KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $635.59 across this reporting matrix range.

Provider Avg Cost Per Claim

$21.92

State Avg Cost Per Claim

$18.90

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Montelukast is used to control and prevent symptoms caused by asthma (such as wheezing and shortness of breath). It is also used before exercise to prevent breathing problems during exercise (bronchospasm). This medication can help decrease the number of times you need to use your quick relief inhaler. Montelukast is also used to relieve symptoms of hay fever and allergic rhinitis (such as sneezing, stuffy/runny/itchy nose). Since there are other allergy medications that may be safer (see also Warning section), this medication should be used for this condition only when you cannot take other allergy medications or they do not work well. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If an asthma attack or sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This drug works by blocking certain natural substances (leukotrienes) that may cause or worsen asthma and allergies. It helps make breathing easier by reducing swelling (inflammation) in the airways.

Mycophenolate Mofetil

Generic Formulation: Mycophenolate MofetilSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 31
30-Day Fills 43.1
Days Supply 1,113
KS State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills44.6
Peer Average Days Supply1,311
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,789.87 across this reporting matrix range.

Provider Avg Cost Per Claim

$122.25

State Avg Cost Per Claim

$116.68

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.

Therapeutic Applications

Mycophenolate is used in combination with other medications to keep your body from attacking and rejecting your transplanted organ (such as kidney, liver, heart). It belongs to a class of medications called immunosuppressants. It works by weakening your body's defense system (immune system) to help your body accept the new organ as if it were your own.

Prednisone

Generic Formulation: PrednisoneSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 135
30-Day Fills 165.3
Days Supply 3,354
KS State Average Benchmarks
Peer Average Claims43.0
Peer Average 30-Day Fills51.9
Peer Average Days Supply916
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 214.0% higher than the standard regional baseline profile for KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $703.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.21

State Avg Cost Per Claim

$5.77

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Pulmicort Flexhaler

Generic Formulation: BudesonideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 460
KS State Average Benchmarks
Peer Average Claims15.0
Peer Average 30-Day Fills20.1
Peer Average Days Supply594
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,543.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$283.98

State Avg Cost Per Claim

$298.75

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A glucocorticoid used in the management of ASTHMA, the treatment of various skin disorders, and allergic RHINITIS.

Therapeutic Applications

Budesonide is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma. This medication belongs to a class of drugs known as corticosteroids. It works directly in the lungs to make breathing easier by reducing the irritation and swelling of the airways. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler as prescribed.

Spiriva Handihaler

Generic Formulation: Tiotropium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 19.0
Days Supply 570
KS State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills23.2
Peer Average Days Supply692
Conservative Utilization

This provider writes prescriptions for this formulation 27.8% less frequently than the standard regional baseline metric for practitioners inside KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $14,093.24 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,084.10

State Avg Cost Per Claim

$675.53

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

Tiotropium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Spiriva Respimat

Generic Formulation: Tiotropium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 40
30-Day Fills 78.0
Days Supply 2,340
KS State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills31.0
Peer Average Days Supply928
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 60.0% higher than the standard regional baseline profile for KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $38,654.93 across this reporting matrix range.

Provider Avg Cost Per Claim

$966.37

State Avg Cost Per Claim

$646.21

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

Tiotropium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Symbicort

Generic Formulation: Budesonide/Formoterol FumarateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 101
30-Day Fills 148.0
Days Supply 4,440
KS State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills38.7
Peer Average Days Supply1,159
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 236.7% higher than the standard regional baseline profile for KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $60,128.67 across this reporting matrix range.

Provider Avg Cost Per Claim

$595.33

State Avg Cost Per Claim

$496.08

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: budesonide and formoterol. Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Trelegy Ellipta

Generic Formulation: Fluticasone/Umeclidin/VilanterSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 115
30-Day Fills 168.0
Days Supply 5,040
KS State Average Benchmarks
Peer Average Claims43.0
Peer Average 30-Day Fills54.3
Peer Average Days Supply1,624
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 167.4% higher than the standard regional baseline profile for KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $115,138.21 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,001.20

State Avg Cost Per Claim

$825.83

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 3 medications: fluticasone, umeclidinium, and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling of the airways in the lungs to make breathing easier. Umeclidinium belongs to a class of drugs known as anticholinergics and vilanterol is a LABA medication. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Both drugs are also known as bronchodilators. When used alone, long-acting beta agonists (such as vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination products containing both an inhaled corticosteroid and long-acting beta agonist, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with two asthma-control medications (such as inhaled corticosteroid and long-acting beta agonist) or if your symptoms need combination treatment. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed.

Ventolin Hfa

Generic Formulation: Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 33
30-Day Fills 35.8
Days Supply 819
KS State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills25.6
Peer Average Days Supply590
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 50.0% more claims than the standard regional baseline profile for KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,546.31 across this reporting matrix range.

Provider Avg Cost Per Claim

$77.16

State Avg Cost Per Claim

$74.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Wixela Inhub

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 29
30-Day Fills 53.0
Days Supply 1,590
KS State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills25.3
Peer Average Days Supply760
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 61.1% higher than the standard regional baseline profile for KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $11,515.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$397.10

State Avg Cost Per Claim

$280.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Zolpidem Tartrate

Generic Formulation: Zolpidem TartrateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 21.0
Days Supply 630
KS State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills54.9
Peer Average Days Supply1,621
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 70.5% less volume than the regional standard for practitioners inside KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $100.34 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.72

State Avg Cost Per Claim

$9.35

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.

Therapeutic Applications

Zolpidem is used for a short time to treat a certain sleep problem (insomnia) in adults. If you have trouble falling asleep, it helps you fall asleep faster, so you can get a better night's rest. Zolpidem belongs to a class of drugs called sedative-hypnotics. It acts on your brain to produce a calming effect.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MONTGOMERY L ROBERTS D.O. provides transparency into local medical care patterns within Shawnee Mission, KS.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Pulmonary Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.